QUESTION: My doctor just told me that I have fatty liver disease. She says that in my case it has nothing to do with drinking alcohol, which makes sense since I rarely drink. But I still don't understand it. She says it has to do with the fact that I've been overweight most of my life.

ANSWER: Nonalcoholic fatty liver disease (NAFLD) was rarely diagnosed before 1980. But today, it is believed to affect as many as 30% of adult Americans.

Nonalcoholic fatty liver disease is actually not a single disease. Instead, it's a spectrum of disorders, all marked by the accumulation of fat inside liver cells. Under the microscope, this fatty buildup looks just like alcohol-induced fatty liver disease, but it occurs in people who consume little or no alcohol.

Nonalcoholic fatty liver disease usually causes no symptoms and few, if any, complications. However, some people go on to develop serious problems.

The exact cause of NAFLD is unknown. But its emergence as a recognized and increasingly common disorder coincides with the epidemics of obesity and Type 2 diabetes. Both of these are associated with insulin resistance.

Obesity and insulin resistance, in turn, are implicated in metabolic syndrome, a group of risk factors that increase the risk of cardiovascular disease, including a large waist and high triglycerides (a type of blood fat). Some experts consider nonalcoholic fatty liver disease a symptom of metabolic syndrome.

The leading theory about nonalcoholic fatty liver disease is that it's a result of metabolic changes driven by insulin resistance. More fat stays in the liver, accumulating in tiny sacs in the liver cells.

In its simplest form, nonalcoholic fatty liver disease is just fat in the liver cells. This condition is called steatosis. While steatosis is not normal, it causes no symptoms and by itself is usually harmless. However, 5% to 20% of people with steatosis will develop a more serious form of nonalcoholic fatty liver disease called nonalcoholic steatohepatitis, or NASH. In NASH, the fattened cells cause inflammation, swelling and cell death.

We don't know the cause of this more serious, inflammatory form of nonalcoholic fatty liver disease or who is most likely to develop it, but it is not simply related to the amount of fat in the liver cells.

NASH is usually a relatively stable condition with few symptoms. Most people don't know they have it unless it shows up during a blood test or imaging procedure performed for other reasons. But unlike steatosis, NASH is not harmless.

Visit link:
Harvard Medical School Adviser: Lifestyle changes help combat liver disease

by Emily Gersema - Mar. 4, 2012 09:29 PM The Republic | azcentral.com

The University of Arizona is asking state lawmakers for $15 million in state funds for its downtown Phoenix medical campus next school year so it can boost enrollment and hire more professors.

Rep. Ted Vogt, R-Tucson, is sponsoring House Bill 2551, which, if approved, would increase the UA Phoenix campus' budget by an estimated $540,000 from the $14.36 million in state funding approved by legislators for this school year.

"This is a strategic investment," Vogt said. "It's not just an investment in a university or education, it's an investment that will produce more doctors who will go out and serve the state of Arizona."

Vogt and other proponents of the campus say its flagship program, the UA College of Medicine-Phoenix, is producing new doctors who can provide health care in underserved areas, such as poor and rural communities. Vogt said the campus is helping to address issues with shortages of medical professionals.

The campus graduated its first class of medical doctors -- 24 students -- last spring and currently has 192 students.

Also growing the student population downtown is the addition of Northern Arizona University, which next year will draw some 50 students to the UA campus with its physical-therapy and physicians-assistant programs.

NAU is moving into the new Health Sciences Education Building at Seventh and Van Buren streets.

Both universities have said they are attempting to keep within the state most of the graduates from their Phoenix campus programs. UA officials note that about half of last year's graduating class of doctors from the campus are in residency in Arizona hospitals.

Vogt anticipates that some members of the Arizona Legislature who consider themselves fiscal conservatives will resist his proposal, but he believes others will see the school's continued financing as critical for boosting the local and state economy.

Read the original here:
Bill would raise UA medical campus funding

Public release date: 1-Mar-2012 [ | E-mail | Share ]

Contact: Mark Shelton mark.shelton@umassmed.edu 508-856-2000 University of Massachusetts Medical School

Cambridge, Mass., and Worcester, Mass., March 1, 2012 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and the University of Massachusetts Medical School (UMMS) reported today that the European Patent Office (EPO) has upheld the Tuschl I '726 patent (EP 1309726) in oral opposition proceedings held in Munich, Germany. The requested claims of the '726 patent were upheld without any modification. Opponents included Sanofi-Aventis Deutschland GmbH, Silence Therapeutics AG, and BASF SE.

Inventors on the patent are David P. Bartel, PhD, a Howard Hughes Medical Institute Investigator and professor of biology at the Massachusetts Institute of Technology; Phillip A. Sharp, PhD, Institute Professor at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology and a 1993 Nobel Laureate; Thomas Tuschl, PhD, a Howard Hughes Medical Institute Investigator and professor at Rockefeller University; and Phillip D. Zamore, PhD, a Howard Hughes Medical Institute Investigator and the Gretchen Stone Cook Professor of Biomedical Sciences at the University of Massachusetts Medical School, where he co-directs the RNA Therapeutics Institute.

"The Tuschl family of patents defines key discoveries central to the advancement of RNAi therapeutics to patients," said James P. McNamara, PhD, executive director, Office of Technology Management, University of Massachusetts Medical School. "The Tuschl I patent is a critical invention by Professors Tuschl, Zamore, Bartel, and Sharp regarding the RNAi mechanism. We are pleased to see this patent fully upheld in Europe in these opposition proceedings."

"We are very pleased with the outcome of these opposition proceedings which resulted in the claims from the Tuschl I '726 patent being fully upheld. This decision by the EPO affirms our belief in the validity of these claims, and the novelty of the Tuschl I invention, and supports the relevance of Tuschl I for the development and commercialization of RNAi therapeutics," said Laurence Reid, PhD, senior vice president and chief business officer of Alnylam. "Alnylam continues to leverage its leading patent estate for the advancement of innovative medicines to patients and also continues to enable the entire RNAi therapeutics field with over 30 license agreements formed to date."

"The research discoveries that form the basis for this patent were a significant milestone in the explication of the basic science of RNAi and the path to the world of RNA therapeutics," said Zamore. "The affirmation of the intellectual basis of these discoveries by the EPO will accelerate the opportunities for laboratories and research organizations around the world to use this science to work toward therapeutics to treat human disease."

Alnylam is the co-exclusive licensee of the Tuschl I '726 patent which is owned by the Max Planck Society, the Massachusetts Institute of Technology, the Whitehead Institute for Biomedical Research, and the University of Massachusetts Medical School. This patent is a key component to Alnylam's fundamental intellectual property estate that comprises numerous issued or granted patents and a large number of pending patent applications that together broadly cover RNAi therapeutics, including small interfering RNAs, or siRNAs, the molecules that mediate RNAi. The Tuschl I '726 patent consists of 14 claims broadly covering RNAi methods, including methods of reducing the expression of a gene, with double stranded RNAs between 21 and 23 nucleotides in length of mammalian or viral origin. The patent also includes claims covering methods of examining the function of a gene, as well as the use of both unmodified and chemically modified double stranded RNAs.

About RNA Interference (RNAi)

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNAs (siRNAs), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, target the cause of diseases by potently silencing specific mRNAs, thereby preventing disease-causing proteins from being made. RNAi therapeutics have the potential to treat disease and help patients in a fundamentally new way.

Link:
Alnylam and UMass Medical School announce Tuschl I patent upheld in European opposition proceedings

Dr. Fred Wang, interim director of Harvard Medical Schools New England Primate Research Center, has stepped down, a Harvard Medical School spokesperson confirmed this morning.

Wangs departure comes shortly after the school announced it will suspend new experiments at the center in the wake of the death of a cottontop tamarin monkey at the facility Sunday.

That death was the third death at the center since October 2011 and the fourth death there in the last 21 months.

Harvard Medical School dean Jeffrey Flier called the deaths absolutely unacceptable, deeply regrettable and personally disturbing to me in a strongly worded statement this week, and vowed to take aggressive action to resolve systems, processes and human errors at the facility.

When I learned of the most recent incident on Sunday, I immediately halted all new research protocols and new research on existing protocols at the (New England Primate Research Center), Flier wrote. The goal of this action is to provide time for our personnel to create and implement a corrective action plan.

See more here:
Southborough Primate Center director steps down

by Art Thomason - Mar. 2, 2012 02:11 PM The Republic | azcentral.com

A well-known Valley doctor who helped establish a Missouri-based university's medical school in Mesa will lead the university as its new president.

Dr. Craig Phelps, who also serves as the Phoenix Suns' primary-care physician, was selected for the post at A.T. Still University of Health Sciences in Kirksville, Mo., after an extensive search that included a number of national leaders in health-care education, according to university officials. The appointment becomes effective July 1.

Phelps is provost of the university's Mesa campus and has been a member of the Suns' medical staff for 26 years, providing non-orthopedic care for players and other team employees.

"I am honored and humbled to be selected by the board as ATSU's next president," said the 55-year-old physician and scholar. "I will continue to work closely with President (Jack) Magruder to ensure a smooth transition.

"With everyone's help, we will bring ATSU to the next level and achieve the board's vision of preeminence."

Phelps has been involved in the university's Mesa campus development since 2001 when the university moved its Arizona health sciences programs to Mesa from its first Arizona location at Grand Canyon University in Phoenix.

In 2003, the university opened Arizona's first dental school on the Mesa campus, the Arizona School of Dentistry & Oral Health. In 2007, the campus' four-year college of osteopathic medicine accepted its first class of students.

The 50-acre campus is the only one of its type in the state with a comprehensive curriculum of disciplines in medicine, dentistry and health care.

Phelps said university officials had long supported the idea of opening a medical school in Mesa.

Read the original:
Mesa doctor new president of Missouri-based university

VANCOUVER A former University of British Columbia medical school employee is on the hook for more than a half a million dollars after she secretly accepted almost twice the pay she was owed.

Dating back to 1998, Wanda Barbara Moscipan, a financial administrator at the school, received $610,427.82 she wasn't entitled to, according to B.C. Supreme Court documents.

Moscipan's employment arrangement with the school stipulated that 20 per cent of her salary would be paid by UBC, while 80 per cent would be covered by Vancouver Coastal Health.

In its termination notice to Moscipan, the school accused her of fraudulently accepting 100 per cent of her pay from the school, and an additional 80 per cent from the health authority.

"Effectively, Ms. Moscipan claimed and received an income amounting to 180 per cent of pay for 100 per cent of work," Justice Richard Blair wrote in his Tuesday ruling.

The judge granted the school an injunction to try and recoup its money.

"My order freezes Ms. Moscipan's assets before judgment and also permits UBC to obtain information about Ms. Moscipan's assets through access to her banking and other financial records," the judge wrote.

He said he was convinced Moscipan tried to bilk the school of its money, and he believed there was a real risk that she could hide or get rid of her assets.

Moscipan was fired from her job in the Department of Obstetrics and Gynecology in November 2011.

The injunction comes on the heels of the conviction of John Mwotassubi, a former financial manager in UBC's pediatrics department, who admitted to stealing nearly $460,000 from the school over seven years, dating back to 2003.

See more here:
Former UBC staffer must repay $600,000 in excess salary: judge

CAMBRIDGE, Mass. & WORCESTER, Mass.--(BUSINESS WIRE)--

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, and the University of Massachusetts Medical School (UMMS) reported today that the European Patent Office (EPO) has upheld the Tuschl I 726 patent (EP 1309726) in oral opposition proceedings held in Munich, Germany. The requested claims of the 726 patent were upheld without any modification. Opponents included Sanofi-Aventis Deutschland GmbH, Silence Therapeutics AG, and BASF SE.

Inventors on the patent are David P. Bartel, Ph.D., a Howard Hughes Medical Institute Investigator and professor of biology at the Massachusetts Institute of Technology; Phillip A. Sharp, Ph.D., Institute Professor at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology and a 1993 Nobel Laureate; Thomas Tuschl, Ph.D., a Howard Hughes Medical Institute Investigator and professor at Rockefeller University; and Phillip D. Zamore, Ph.D., a Howard Hughes Medical Institute Investigator and the Gretchen Stone Cook Professor of Biomedical Sciences at the University of Massachusetts Medical School, where he co-directs the RNA Therapeutics Institute.

The Tuschl family of patents defines key discoveries central to the advancement of RNAi therapeutics to patients, said James P. McNamara, Ph.D., Executive Director, Office of Technology Management, University of Massachusetts Medical School. The Tuschl I patent is a critical invention by Professors Tuschl, Zamore, Bartel, and Sharp regarding the RNAi mechanism. We are pleased to see this patent fully upheld in Europe in these opposition proceedings.

We are very pleased with the outcome of these opposition proceedings which resulted in the claims from the Tuschl I 726 patent being fully upheld. This decision by the EPO affirms our belief in the validity of these claims and the novelty of the Tuschl I invention, and supports the relevance of Tuschl I for the development and commercialization of RNAi therapeutics, said Laurence Reid, PhD, Senior Vice President and Chief Business Officer of Alnylam. Alnylam continues to leverage its leading patent estate for the advancement of innovative medicines to patients and also continues to enable the entire RNAi therapeutics field with over 30 license agreements formed to date.

The research discoveries that form the basis for this patent were a significant milestone in the explication of the basic science of RNAi and the path to the world of RNA therapeutics, said Zamore. The affirmation of the intellectual basis of these discoveries by the EPO will accelerate the opportunities for laboratories and research organizations around the world to use this science to work toward therapeutics to treat human disease.

Alnylam is the co-exclusive licensee of the Tuschl I 726 patent which is owned by the Max Planck Society, the Massachusetts Institute of Technology, the Whitehead Institute for Biomedical Research, and the University of Massachusetts Medical School. This patent is a key component to Alnylams fundamental intellectual property estate that comprises numerous issued or granted patents and a large number of pending patent applications that together broadly cover RNAi therapeutics, including small interfering RNAs, or siRNAs, the molecules that mediate RNAi. The Tuschl I 726 patent consists of 14 claims broadly covering RNAi methods, including methods of reducing the expression of a gene, with double stranded RNAs between 21 and 23 nucleotides in length of mammalian or viral origin. The patent also includes claims covering methods of examining the function of a gene, as well as the use of both unmodified and chemically modified double stranded RNAs.

About RNA Interference (RNAi)

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as a major scientific breakthrough that happens once every decade or so, and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNAs (siRNAs), the molecules that mediate RNAi and comprise Alnylams RNAi therapeutic platform, target the cause of diseases by potently silencing specific mRNAs, thereby preventing disease-causing proteins from being made. RNAi therapeutics have the potential to treat disease and help patients in a fundamentally new way.

About Alnylam Pharmaceuticals

Follow this link:
Alnylam and the University of Massachusetts Medical School Announce Tuschl I Patent Upheld in European Opposition ...

New experiments at Harvard Medical Schools New England Primate Research Center have been suspended after a cottontop tamarin monkey died at the facility on Sunday, the fourth primate death there in 21 months.

Calling the deaths of four primates at the Southborough facility absolutely unacceptable, deeply regrettable and personally disturbing to me, Jeffrey Flier, dean of Harvard Medical School, vowed to take aggressive action to resolve systems, processes and human errors at the facility.

When I learned of the most recent incident on Sunday, I immediately halted all new research protocols and new research on existing protocols at the (New England Primate Research Center), Flier said in a statement. The goal of this action is to provide time for our personnel to create and implement a corrective action plan.

Harvard Medical School is assembling an independent review committee to assess the facilitys logistics and management and established a team led by veterinary staff and supervisors who will perform additional daily checks verifying the heath and wellness of every animal.

We will do this until we are convinced that systems are in place to ensure the well-being of the animals, said Flier.

Harvard Medical School declined to release details of the monkeys death.

United States Department of Agriculture spokesman David Sacks said he did not have details of the monkeys death because the USDA has not investigated yet. The USDA will send an inspector to Southborough soon.

Officials at the Primate Center reported the monkeys death Sunday night to the USDA, the same day the agency released an inspection revealing three incidents in which several monkeys were injured and a squirrel monkey died because of employee carelessness. The facility is facing tens of thousands of dollars in fines.

Harvard did self-report that fourth incident to us, said Sacks. We were made aware of that.

Describing the past 21 months where three other primates died in December 2011, October 2011 and June 2010 as a tough stretch, Sacks said the USDA has the Southborough facility on its radar.

Continue reading here:
Harvard halts research in Southborough after fourth monkey dies

NEW YORK, Feb. 29, 2012 /PRNewswire/ --(http://www.myprgenie.com) -- The seventh annualCastle Connolly Medical Ltd. National Physician of the Year Awardswill take place on Monday evening, March 26, 2012 at The Pierre Hotel in New York City. The Awards recognize and honor five exemplary physicians, as well as the many thousands of other excellent physicians practicing in communities throughout the United States. The evening will begin at 6:30PM with cocktails followed by dinner and the awards presentation. Tickets are $200 each.

Awards are given to physicians who are nationally recognized leaders and contributors in their specialties.

TheLifetime Achievement Awardis awarded to physicians for their lifetime of dedication to research and practice in their respective fields. This year, the award will be presented to:

TheClinical Excellence Award, recognizing physicians who exemplify excellence in clinical medical practice, will be presented to:

TheNational Health Leadership Awardis awarded to a non-physician outstanding dedication and work with an organization has heightened the awareness for the need of support and research for that specific cause.Marlo Thomas, National Outreach Director ofSt. Jude Children's Research Hospitalwill receive this year'sNational Health Leadership Award.

John K. Castle,Chairman, andJohn J. Connolly, Ed.D., President and CEO, ofCastle Connolly Medical Ltd.William Liss-Levinson, Ph.D.,Vice President,Chief Strategy & Operations Officer, Castle Connolly Medical Ltd. andJean Morgan, M.D.,Vice President, Chief Medical & Research Officer, Castle Connolly Medical Ltd. will be among the Awards Presenters for the evening.Dr. Steve Salvatore, host of "Dr. Steve," Tribune's nationally syndicated TV show, will be the Master of Ceremonies for the evening.

About the National Physician of the Year Awards

Each year,Castle Connolly Medical Ltd.receives thousands of nominations from physicians and the medical leadership of major medical centers, specialty hospitals, teaching hospitals as well as regional and community medical centers across the United States as an integral part of our research, screening and selection process to identifyAmerica's Top Doctors(R).The selected physicians, while located in all 50 states and involved in more than 70 medical specialties and subspecialties, all share one distinguishing professional attribute: an unwavering dedication to their patients and to medicine as a whole. Each and every one of these outstanding medical professionals is a symbol of the clinical excellence that characterizes American medicine. In honor of these outstanding physicians, as well as the many thousands of other excellent physicians practicing in communities throughout the United States,Castle Connolly Medical Ltd.created the National Physician of the Year Awards.

About Castle Connolly Medical Ltd.

Castle Connolly Medical Ltd. is America's trusted source for identifying top doctors. Founded in 1991 byJohn K. Castle, (Chairman) andJohn J. Connolly, Ed.D.(President and CEO), who served as board chairman, and president and CEO of New York Medical College, respectively, its mission is to help consumers find the best healthcare. They achieve that mission through their consumer books -- such asAmerica's Top Doctors(R)-- their web site and various consumer and business-oriented print and online partnerships. Under the direction of its physician-lead research team,Castle Connollysurveys tens of thousands of physicians and hospital executives in order to identify, screen and, ultimately, select those physicians regarded by their peers as leaders - among the very best -- in their specialties and for specific diseases and techniques. The members of the management team include Jean Morgan, M.D., Vice-President, Chief Medical & Research Officer and William Liss-Levinson, Ph.D., Vice-President, Chief Strategy & Operations Officer.Castle Connolly'svaluable top doctors information can also be found online atwww.castleconnolly.com.

See original here:
Castle Connolly Medical Ltd. Honors Top Physicians at Seventh Annual National Physician of the Year Awards Monday ...

Public release date: 1-Mar-2012 [ | E-mail | Share ]

Contact: Heather Curry PR@acr.org 703-390-9822 American College of Radiology

Reston, VA -- A medical school in Ireland has successfully implemented a radiation protection program, improving knowledge of radiation protection among medical undergraduates, according to a study in the March issue of the Journal of the American College of Radiology.

Although the increased use of diagnostic imaging has resulted in faster, more accurate diagnosis, better assessment of therapy response, and early detection of complications, there has been a great deal of scrutiny of its increasing use. As a result, there is a growing need for medical professionals to be educated in all aspects of diagnostic imaging to ensure a basic understanding of imaging technology, appropriate and efficient utilization of diagnostic imaging investigations, basic image interpretation and possible adverse effects of exposure to ionizing radiation.

An e-learning module in radiation protection was designed and presented to year four medical undergraduates at University Cork College in Cork, Ireland. All students were required to complete pre-module and post-module questionnaires.

Eighty-nine percent and 99 percent of the 127 medical students successfully completed and returned the pre-module and post-module questionnaires.

"After the e-learning module, students' post-module radiation protection knowledge had improved significantly," said Sum Leong, MB, lead author of the study.

Analysis of post-module radiation protection knowledge suggested that a favorable self-assessment of knowledge of radiation protection, perception of career prospects in radiology and completion of the e-learning module with an increased number of sessions were factor predictive of improved radiation protection knowledge.

"The undergraduate medical curriculum is undergoing constant review and modification in response to modern medical developments that are changing clinical practice. The introduction of radiation protection into undergraduate curriculum therefore requires careful planning to maximize the effectiveness of the course while avoiding overburdening undergraduates with unmanageable lecture and tutorial schedules," said Leong.

"Combining e-learning and more traditional educational programs such as a clinical radiology rotation is likely to improve student experience," he said.

Continued here:
Medical School implements successful radiation protection program for undergraduate medical students

Medical school students have had an increasing appetite for business knowledge to better prepare them for their careers. In response to that, West Virginia University has created its M.D./M.B.A.

Morgantown, West Virginia (PRWEB) February 29, 2012

The two schools have collaborated to create the M.D./M.B.A. for medical school students during an optional step out year in the medical school curriculum, which occurs at the conclusion of their second year of study.

WVU President Jim Clements said the partnership between the two schools demonstrates how collaboration can help provide students with the skills needed to meet the challenges of todays world.

Interdisciplinary collaborations like this one are important for our students, Clements said. I applaud the faculty and staff at both B&E and Medicine for partnering to create this unique academic opportunity.

Provost Michele Wheatly emphasized the ways in which the new program exemplifies WVUs strategic goals. This is an example of transforming a curriculum at the highest level, she said. This program will engage students and faculty not only across disciplines but across campuses, with exciting implications for real-world impact.

This partnership represents a collaborative effort to offer a critical component of business education to WVU medical school students, Arthur J. Ross, III, M.D., M.B.A., dean of the WVU School of Medicine, said. Todays world demands that professionals be business savvy, and the medical profession is certainly no exception to that. All students need this exposure but there are some who need the intense type of exposure that can only be provided by an M.B.A. program. Those students who envision themselves in positions of significant, high level administrative leadership anywhere in the medical arena would be examples of ideal candidates for this program.

With increasing pressures due to changes in the medical industry, physicians will have to better understand the revenue streams and cost implications of their practices or organizations. An M.B.A. will increase their understanding of the business side of medical practices, and thats a huge plus, said Dr. Ross, who holds an M.B.A. in addition to his medical degree.

Wheatly agreed. Were giving our students the tools to be truly innovative practitioners of medicine, she said. These are the doctors who will become leaders in their chosen fields.

Prospective students would apply to the WVU School of Medicine and to the M.B.A. program at the same time, said Dr. Jose Sartarelli, Milan Puskar Dean, WVU College of Business and Economics. They would be admitted to both programs, which would allow them to step out to complete the M.B.A. after their second year. After they take a year to obtain the M.B.A., then they will resume their medical school curriculum.

More:
WVU Business and Medical Schools Create New Program to Give Medical School Students Critical Business Knowledge

WAUSAU (WAOW) -

Aspirus says plans to build a medical school in Wausau are not feasible.

But the group leading the effort says Wausau is still the top choice for establishing the medical school.

Aspirushad beenworking with the Wisconsin College of Osteopathic Medicine (WCOM), trying to decide if establishing an osteopathic medical school on the Aspirus campus in Wausau would work.

On Tuesday, Aspirus announced the model for the school was not feasible.

Aspirus officials said their decision came down to two things: money and control. They said it would have cost $75 million to build the school, but five different medical providers would have had to contribute money.

They also said there were concerns about how the school would be run.

"With five health care systems who are competing, potentially some with each otheras owners of the school, in the governance, involved in the decision making of the schoolit was felt that maybe the interest of the school itself and its students would become secondary," said Sid Sczygelski, Aspirus chief financial officer.

But WCOM leaders say it goes beyond that. Dr. Gregg Silberg, executive vice president and dean of WCOM, said the proposed model would not have allowed the medical school to be accredited.

Silberg also said WCOM is still working to establish the medical school in Wausau.

Read the rest here:
Proposed medical school will not move to Wausau

Harvard Medical School could face tens of thousands of dollars in fines after a third monkey died at the school’s Southborough research center, a U. S. Department of Agriculture spokesman said yesterday.

A squirrel monkey’s death on Dec. 26, 2011 was one of three new citations Harvard’s New England Primate Research Center received in a Jan. 31 inspection. The results of that inspection were released Sunday.

“To look at this inspection report and see three direct non-compliances — that’s a big deal,” said David Sacks, a USDA spokesman.

This is the third primate death in 19 months at the facility.

The latest inspection describes three incidents where several monkeys were injured and one died because of employee carelessness.

Sacks said the latest report is especially serious because all three citations are “direct non-compliance issues,” meaning the animal’s welfare was directly affectedby each misstep.

“That’s kind of top on the list you don’t want to be on,” Sacks said.

According to the report, a malfunctioning water dispenser led two monkeys to become dehydrated. One recovered but the other was euthanized.

In addition, a squirrel monkey’s leg was fractured in a cage door. A rhesus macaque monkey injured his foot after he and others escaped from a pen.

Harvard Medical School on Sunday released a lengthy statement about its shortfalls.

“Our recent systems lapses are unacceptable and deeply troubling to us,” the statement says.

These are the latest in a string of USDA violations at the facility in two years, many of which Harvard reported itself.

Two other primates died in Southborough, one in October and one in June 2010. Another died at a different Harvard Medical School facility in February 2011 from an anesthesia overdose.

“They’re not having a good stretch right now,” Sacks said.

The Southborough facility conducts research on the cause and treatment of HIV and other diseases including colon cancer and sickle cell anemia.

The facility has 2,058 monkeys and a staff of 190 faculty, fellows and support personnel. It has been registered with the USDA since 1967 and has made many major breakthroughs including producing the first unambiguous evidence that AIDS is caused by a virus.

Sacks said the USDA has not yet determined the penalty Harvard will face. The investigation could take up to a year.

USDA investigators are combining past and recent citations to determine how many times the facility violated the Animal Welfare Act.

“It’s all going to get wrapped up into one big investigation,” Sacks said.

Each violation is punishable with a fine of up to $10,000.

“They’re looking at a penalty, no doubt,” Sacks said.

Harvard’s statement is the only communication it has issued since the report’s release on Sunday.

The document outlines steps it plans to take to address the problems, including more closely monitoring the watering system and cages and re-training staff.

Michael Budkie, executive director of Stop Animal Cruelty Now! said his animal rights organization would like a more in-depth investigation of the facility.

“There is clearly a system-wide epidemic of fatal negligence at all of these Harvard-connected facilities,” Budkie said.

Per USDA guidelines, the facility will be subject to an unannounced reinspection in the next 45 days.

(Laura Krantz can be reached at 508-626-4429 or lkrantz@wickedlocal.com. Follow her on Twitter@laurakrantzmwdn.)

View original post here:
Southborough primate research center may face fines

Ohio student: 'We were at a loss'

STORY HIGHLIGHTS

A second victim dies, amedical examiner says Witnesses say T.J. Lane shot five people in an Ohio high school cafeteria Lane is scheduled for a juvenile court hearing Tuesday "Die, all of you," Lane wrote in Facebook in December

Chardon, Ohio (CNN) -- A second victim has died from wounds suffered in the school shooting in Chardon, Ohio, the Cuyahoga County Medical Examiner's office said Tuesday.

Russell King Jr., 17, was declared brain dead early Tuesday, according to the medical examiner's office. He was shot at Chardon High School on Monday, the agency said in a written statement.

Student Daniel Parmertor died on Monday. Three other students were wounded in the shooting.

Authorities have yet to name the teen shooter arrested in the Monday morning attack. But many students, some of whom said they were steps away from the suspect when the bullets flew, described the shooter as a withdrawn boy named T.J. Lane.

The suspect was scheduled to make an initial court appearance at 3:30 p.m. Authorities have not released the charges the 17-year-old sophomore may face.

Lawyer Bob Farinacci, speaking for Lane's family, said late Monday night that the 17-year-old was "extremely remorseful."

"Very, very scared and extremely remorseful," he told CNN affiliate WKYC.

"He is a very confused young man right now," Farinacci added. "He's very confused. He is very upset. He's very distraught ... himself. This is a very scary circumstance that I don't think he could have possibly even foreseen himself in the middle of."

There will be no school Tuesday in Chardon, where parents and children struggle to understand the inexplicable actions of a quiet teen that upended the calm of the small suburban Cleveland community.

"I want people to stay home tomorrow to reflect on their families," said Superintendent Joe Bergant, choking with emotion at a Monday afternoon news conference, "and if you haven't hugged or kissed your kid, do."

Like others in the town of 5,100, Lane's family has been left grappling for an explanation, he said.

"This is something that could never have been predicted," Farinacci said. "TJ's family has asked for some privacy while they try to understand how such a tragedy could have occurred and while they mourn this terrible loss for their community."

With little to go on, many turned to cryptic Facebook postings by the alleged shooter for a glimpse into Lane's mindset -- especially a long, dark poetic rant from December 30.

The post refers to "a quaint lonely town, (where there) sits a man with a frown (who) longed for only one thing, the world to bow at his feet."

"He was better than the rest, all those ones he detests, within their castles, so vain," he wrote.

Lane then wrote about going through "the castle ... like an ominous breeze through the trees," past guards -- all leading up to the post's dramatic conclusion.

"Feel death, not just mocking you. Not just stalking you but inside of you," he writes. "Wriggle and writhe. Feel smaller beneath my might. Seizure in the Pestilence that is my scythe."

He concluded the post with: "Die, all of you."

On Monday just before class started, witnesses say Lane silently walked up to a table of students, holding a gun.

As he opened fire, the shooter was expressionless, a student recalled.

"He was silent the entire time," said student Nate Mueller, who said his ear was grazed by a bullet. "There was no warning or anything. He just opened fire."

Danny Komertz, a freshman, said the shooter seemed to be focused on specific targets.

"I looked straight ahead and I saw a gun pointing at a group of four guys sitting a table. ... He just fired two quick shots at them. I saw one student fall, and I saw the other hiding, trying to get cover underneath the table," Komertz said.

"He was aiming right at them as he was two feet away. ... He wasn't shooting around the cafeteria at all. He was directly aiming at the four of them," he said.

In a school, which drills students on what to do in emergencies, Monday's death toll may have been much higher were it not for the actions of assistant football coach and study hall teacher Frank Hall, students said.

Hall chased the gunman out of the school, and police arrested the suspect nearby a short time later.

"Coach Hall, he always talks about how much he cares about us students, his team and everyone. And I think today he really went out and he proved how much he cared about us. He would take a bullet for us," said student Neil Thomas.

The victims were students who attended Lake Academy Alternative School, a nearby vocational school, and were waiting for a bus to take them there, witnesses said. Lane himself is a student at the school for at-risk children, said its interim director, Don Ehas.

In a statement Monday, Parmertor's family said they were "torn by the loss."

"Danny was a bright young boy who had a bright future ahead of him," the family said.

Many juvenile court hearings are closed to the public, so it may still be some time before the northeastern Ohio community gets some answers.

"By all accounts T.J. is a fairly quiet and good kid," said Farinacci, the Lane family attorney, said. "His grades are pretty impressive. He's a sophomore. He's been doubling up on his classes with the intent of graduating this May.

"He pretty much sticks to himself but does have some friends and has never been in trouble over anything that we know about."

CNN's Scott Thompson, Lateef Mungin, Martin Savidge and Lisa Sylvester contributed to this report.

See the article here:
Second student dies from Ohio school shooting

DAVID WAHLBERG | Wisconsin State Journal | dwahlberg@madison.com | 608-252-6125 madison.com | | Posted: Tuesday, February 28, 2012 5:30 pm

The main backer of a proposed osteopathic medical school in Wausau dropped the plan Tuesday, but another organizer vowed to keep pursuing the idea.

Aspirus, a Wausau-based health system, said its plan to pay for and own the $75 million Wisconsin College of Osteopathic Medicine with four other health systems "was not viable" because of competing business interests.

"There was an inconsistency between the best interests of the school and students, and the best interests of the competing health care systems," said Sid Sczygelski, chief financial officer of Aspirus.

Dr. Gregg Silberg, dean of the proposed school, said he is "working with a number of different supporters" to "aggressively move forward" on other plans for the school.

"We're looking at Wausau specifically," Silberg said. "We feel that's the right place to be."

Aspirus and the osteopathic school organization announced their plan for the school in November. In January, the Medical College of Wisconsin in Milwaukee said it was looking at putting "community-based medical school components" in one or more regions of the state.

A Wisconsin Hospital Association report in November predicted a shortage of nearly 2,200 doctors by 2030, especially in primary care.

Dr. Robert Golden, dean of the UW School of Medicine and Public Health, criticized the proposed osteopathic school, saying it would cost more than expanding the two existing medical schools.

Sczygelski said Aspirus and the four other health systems, which he wouldn't name, would have paid $10 million each and borrowed $25 million to build and equip the osteopathic school.

See more here:
Health system nixes plan for new osteopathic medical school in Wausau

The MCAT (Medical College Admission Test) is arguably the most feared and least understood component of the medical school admissions process. To help demystify the test, below is some information about how the test is organized, how it's used in medical school admissions, and whether or not there is a disadvantage to having multiple MCAT scores.

[Read the top three reasons M.D. applications are rejected.]

? What is the test all about? To quickly break it down, the MCAT is composed of four sections: physical sciences, verbal reasoning, and biological sciences--each scored on a scale from 1 to 15--and a writing sample, which is scored from "J" to "T." The highest score possible is a 45-T.

According to the Association of American Medical Colleges (AAMC), the mean MCAT score for all 86,181 people who took the exam in 2011 was 25.1, with a standard deviation of 6.4 and a writing sample score of "O." However, the average MCAT score of those admitted to any allopathic (M.D.) medical school in 2010 was approximately 30. And keep in mind that the average for many medical schools is significantly higher.

? Is it relevant to medicine? The honest answer is both yes and no. If you ask most practicing physicians for help with calculating the magnetic force acting on a wire, or how they would synthesize a polysubstituted aromatic compound from a 3-carbon or less alkyl halide (things they needed to know for the MCAT), they would likely look at you like you have three heads. However, the test does help to reinforce the basic science foundation needed to succeed in medical school.

[Learn whether a postbaccalaureate medical program is right for you.]

? How is it used in the admissions process? Success on the MCAT has been shown to correlate with success on the first part of the United States Medical Licensing Exam (USMLE Step 1). The USMLE Step 1 is typically taken between the second and third year of medical school, right after you complete the preclinical aspect of your medical school education, and just before you begin your clerkships in the hospital.

This is a big deal because most medical schools require passing scores on the USMLE Step 1 before graduation, and it is a critically important part of the residency "match" process. Additionally, it serves as a common, objective measure between all applicants.

? Is there a disadvantage to having multiple MCAT scores? There can be, but it is situation dependent. Many successful applicants don't score commensurate with their abilities on their first MCAT exam. If they analyze their weaknesses, recalibrate their plans, and show a marked improvement the next time, it is unlikely that their decision to take the test a second time will be seen negatively. However, repeated MCAT examinations--three or more--without significant improvement can be a red flag.

[Check out three tips for retaking the MCAT.]

The bottom line is that the admissions committee needs to feel confident that you are capable of succeeding in medical school. If you work diligently during your undergraduate career, excel in your premedical requirements, and prepare intensely for the MCAT, you are setting yourself up for success in the medical school application process and beyond.

Mark D'Agostino, M.D., M.S., M.Sc. is a Brigade Surgeon in the United States Army. As a Marshall Scholar, he earned a master's degree in Biochemistry at the University of Nottingham Medical School, and a second master's in Health Policy, Planning and Financing from the London School of Economics (LSE) and London School of Hygiene and Tropical Medicine (LSHTM). After graduating from Brown Medical School, he trained at Walter Reed Army Medical Center.

Read the original:
Demystifying the MCAT

MINNEAPOLIS--(BUSINESS WIRE)--

MMIC has named Laurie Drill-Mellum, MD, MPH as its first Chief Medical Officer.

In this newly created role, Dr. Drill-Mellum will work closely with MMIC’s Risk Management, Health IT, and Claim departments to develop integrated risk reduction and risk mitigation strategies. She will build a network of physician consultants that will work closely with MMIC clients to deliver risk strategies for physicians and hospitals throughout MMIC’s eight-state region. This physician-to-carrier partnership, which will lead to an integrated risk management strategy for MMIC clients across its entire region, is unique in the medical professional liability industry.

Dr. Drill-Mellum is a Board-certified emergency medicine physician. She is a current Bush Medical Fellow and recently completed a fellowship in Integrative Medicine at the University of Arizona. She will continue her work in emergency medicine part time, and is planning to open a clinic with an integrative medical focus.

According to Bill McDonough, MMIC’s president and CEO, Dr. Drill-Mellum will provide leadership and management from an experienced medical perspective, as well as analysis to help reduce patient injury, the likelihood of lawsuits, and the cost of managing claims. According to McDonough, “This role will serve as a vital link to help MMIC reduce liability costs and differentiate our quality of professional medical liability service. It will also serve as a bridge of support to customers in a time of need, helping them to manage internal and external change.”

Dr. Drill-Mellum holds an undergraduate degree in Anthropology from Pomona College in California. She attended the University of Minnesota Medical School, where she also obtained a Master’s in Public Health. She is a graduate of the Emergency Medicine Residency Program at Hennepin County Medical Center in Minneapolis.

Dr. Drill-Mellum has practiced emergency medicine at Ridgeview Medical Center in Waconia, Minnesota since 1991. During her tenure, she has held roles as both Chief of the Medical Staff as well as Medical Director of the Emergency Department. She is also a Comprehensive Advanced Life Support Instructor.

Dr. Drill-Mellum is a Fellow of the American College of Emergency Physicians. She is a member of the American College of Emergency Physicians, the Minnesota Medical Association, the Twin Cities Medical Society, the American Medical Association, and the American and Minnesota Holistic Physician Associations. She has been on the Board of Directors for MMIC since 2008.

About MMIC Group, Inc.

MMIC Group, Inc. provides professional liability insurance and health information technology services to physicians, clinics, hospitals and other health care facilities and systems, primarily in Minnesota, Iowa, Nebraska, Kansas, Missouri, North Dakota, South Dakota and Wisconsin.

Founded in 1980, MMIC currently insures more than 14,700 health care providers and 430 hospitals and health care facilities. In July A.M. Best Company ranked it as the 20th largest medical professional liability insurer in the United States.

Visit link:
MMIC Names Chief Medical Officer

DELRAY BEACH, Fla., Feb. 28, 2012 /PRNewswire/ -- The Medical Entrepreneur Symposium, a unique educational business meeting for physicians and executives in healthcare, has drawn some of the biggest names in healthcare, technology and wealth management as initial sponsors.

The first in a growing list of symposium sponsors include Citrix GoToMeeting, ADP AdvancedMD, Bernstein Wealth Management, Allergan Cosmetic, Obagi , Merz Aesthetics and BTL Exilis.

"This meeting is the only venue of its kind where physicians can interact with leading companies in technology, electronic health records, practice management, billing services, cosmetic medicine, entrepreneurship, insurance, finance, payroll services and even companies that enable medical practices to innovatively add additional revenue streams," says Dr. Steven Hacker, Founder & Course Director of The Medical Entrepreneur Symposium. The symposium is being held at the Delray Beach Marriott in Delray Beach, Florida, from March 29 through April 1, 2012.

"We have brought together leading experts on every aspect of practice management, healthcare technology, business, finance, cosmetic medicine and entrepreneurship solely for the purpose of teaching doctors what they never learned or had the opportunity to learn in medical school," he says.

The pioneering symposium is based on the popularity of Dr. Hacker's top-selling physician business book, The Medical Entrepreneur Pearls, Pitfalls & Practical Business Advice for Doctors (Nano 2.0 Business Press, 2010).

In two intense sessions over two and a half days, the conference covers issues physicians face in private practice.  The meeting will be kicked off with a keynote speaker sponsored by Citrix GoToMeeting discussing how their technology is transforming healthcare. The meeting also includes lectures from experts on integrating leading healthcare technologies, software and hardware, as well as health records into a practice; billing and getting paid; Medicare and third-party payors; hospital privileges; payroll and human resources; and compliance with new federal regulations. Physicians will be educated on how to add incremental revenue streams and increase patient loyalty through elective and cosmetic medical services. Additionally, physicians are taught how to protect their assets and personal property with lectures on asset protection, wealth preservation, and insuring their personal exposures and understanding their corporate and malpractice risk exposures.  A guest speaker from Bernstein's Wealth Management Division in New York will be flying in to share research and educate physician entrepreneurs on retirement and defined benefit plans.

The second part of the symposium is focused on a new breed of physician: the physician entrepreneur. Doctors often have little training and thus no idea how to raise capital, negotiate a term sheet, deal with institutional and angel investors, create a business plan, incorporate or protect intellectual property. "We cover all of these topics so physicians can feel more comfortable competing on an even playing field with other entrepreneurs looking to raise capital or start a new entrepreneurial venture," says Dr. Hacker. 

Physicians and healthcare executives can register for the meeting online at http://www.TheMedicalEntrepreneur.com. Space is limited. Corporate sponsors may contact Karen Dennis at 877-809-7525 for more information. More information available for media and corporate sponsors through the online press kit at http://www.virtualpressoffice.com/kit/g4sx.

About The Medical Entrepreneur Symposium

The Medical Entrepreneur Symposium (March 29-April 1, 2012 at Delray Beach Marriott) was founded by Dr. Steven Hacker to help physicians become better entrepreneurs in their business and their practice. Dr. Hacker, a phi beta kappa, was barely 20 when he was one of 12 students selected to enter medical school through the prestigious Junior Honors Medical Program. For the last 14 years he has been listed as a Castle Connolly Florida "Top Doctor." He is the top-selling author of the business book, The Medical Entrepreneur (www.TheMedicalEntrepreneur.com), and is published in more than 20 peer-reviewed medical journals. While still practicing medicine in Colorado and Florida, Dr. Hacker has started and sold many well known companies including Skinstore.com and PassportMD. He currently serves as a consultant for many medical device companies.

For more information about The Medical Entrepreneur Symposium, visit http://www.TheMedicalEntrepreneur.com or call 877-809-7525.

Excerpt from:
'The Medical Entrepreneur' Educational Symposium for Physicians Draws Biggest Names in Technology, Health Records ...

A man struggling with drug addiction feels a craving coming on, but his next therapy appointment is not for another week. Right away, his cellphone buzzes, offering a breathing exercise, a motivational message, or even just a distracting game. And his doctor can check on him remotely and alter the messages, if his stress is not alleviated.

For now, this telemedicine scenario is in the future. But in a small pilot program, researchers from the University of Massachusetts Medical School in Worcester and the Massachusetts Institute of Technology have created technologies that will ultimately enable cellphones to automatically detect and intervene when a person suffering from post-traumatic stress disorder or substance abuse problems needs support.

RICH FLETCHER FOR THE BOSTON GLOBE

In a paper published in the Journal of Medical Toxicology, the researchers describe the first generation of the system, which includes wireless sensors that can measure stress symptoms and algorithms capable of crunching data from those sensors to detect patterns that suggest an emerging anxiety attack or drug craving.

“I’ve been doing technology all my life, but the next phase is to apply the technology to real-world problems that are hard,’’ said Rich Fletcher, an assistant professor of psychiatry at UMass Medical School and a research scientist at the MIT Media Laboratory.

Fletcher has cofounded a Cambridge company, Ashametrics, that sells wireless sensing devices, encapsulated in wrist, chest, or ankle bands, to researchers.

As technology has matured, professionals in two different worlds became interested in its potential to offer novel approaches to health care: engineers more used to tinkering with electronics and software and doctors looking for new ways to approach medical problems.

In 2005, Rosalind Picard, a professor at the MIT Media Laboratory, wrote about a future scenario in which evolving technologies, including wireless devices and sensors that can automatically track physical attributes, could be applied to real-world situations, such as helping support people fighting addiction. Those tantalizing possibilities also triggered the interest of Dr. Edward Boyer, a professor of emergency medicine at UMass. The researchers began to work together, focusing on the needs of veterans grappling with substance abuse or post-traumatic stress disorder

RICH FLETCHER FOR THE BOSTON GLOBE

The cellphones and sensors can be used to collect and track data on a patient and help doctors intervene.

.

Fletcher, who has long been involved in designing and engineering wireless sensors, said that while the dream has been around for many years, recent technological improvements now make such a system viable.

Sensors in a wrist or ankle band and a smartphone would not supplant the critical role of a psychiatrist or therapist, Fletcher said, but augment their ability to deliver care and even give doctors a wider window into their patients’ suffering and progress. It could also increase the patient’s engagement in their treatment program.

In the initial study, male veterans with a history of substance abuse problems and post-traumatic stress disorder were recruited to test an early version of the device.

When the phone detected signs of stress from sensors embedded in ankle bands, it prompted the men with a message, asking them if they were OK. If the men said things were not going well, they would be asked if they were experiencing a craving, and what they were doing. People experiencing a craving would receive a supportive message.

Fletcher pinpoints two important areas of future research: studying which intervention messages are most effective in helping patients manage stress and improving the software’s ability to use sensor data to detect what users are feeling or experiencing.

Dr. John Halamka, chief information officer for Beth Israel Deaconess Medical Center, said the technology is part of a wave of innovation in “m-health,’’ or the use of mobile devices in health care.

Such technology will be increasingly important because of the potential to provide continuous monitoring that could prevent serious health problems from developing instead of waiting until people know they need to see a doctor, Halamka said.

“The notion of health care reform is we’re going to be paid for keeping people well, as opposed to treating them while they’re sick,’’ Halamka said.

Try BostonGlobe.com today and get two weeks FREE. Carolyn Y. Johnson can be reached at cjohnson@globe.com. Follow her on Twitter @carolynyjohnson.

Read the rest here:
Medical sensors could phone for help - The Boston Globe

11-02-2012 13:26 Love to all our med school brothers and sisters! DJ Vapor, Sound Engineer: soundcloud.com/dj-vapor Miles Mueller, Director of Photography: Vimeo.com/milesmueller Med students so hard, can't nothing deter us Rotations don't scurr us Finished two years of classes finally we're in the hospital like now it's surrus (Med students so hard) All day rounding Hours we work are astounding Wanna diagnose every patient on the census but we're new to this game and differentials are confounding (Med students so hard) Check the anion gap I'm like a ninja when I do a pap (Med students so hard) Rocking Tdap Everybody wishes they could tap Medicine is happenin', but surgeons get the best toys Bovies, bone saws, babcocks, Ortho boys (Med students so hard) We treat em, where the charts at, we need em Spend all morning writing notes like a boss, but nobody's gonna read em (Med students so hard) Meds immerse us, wash our hands and microbes curse us Our greatest care is patient care Hearts in the right place, no situs inversus (Med students so hard) catching babies, vaccinate against rabies Med mobster, treat zoster, helpin' all of my shingle ladies (Med students so hard) Chug caffeine, titrate Lantus like a machine, They say do a DRE, blushin' like Parvo B-19 Med students so hard, acronyms never end RCA, CVA, DKA Med students so hard, don't know em but we'll pretend tPA, PSA, AMA Patients ask me questions and I spike my cortisol Tachycardic, give us all metoprolol Feelin like C. diff, med ...

View post:
In Clinic (In Paris medical school parody) - Video